Alaunos Therapeutics, Inc. Common Stock (TCRT) Financials
Key financial figures for Alaunos Therapeutics, Inc. Common Stock (Q2 2026).
Alaunos Therapeutics, Inc. reported revenue of $0.00 for Q2 FY2026. The company posted a net loss of $952.0 thousand, or -$0.41 per share. Free cash flow for the period was -$300.0 thousand. The figures above are as filed, and the full income statement, balance sheet and cash flow history for Alaunos Therapeutics, Inc. are on the SentiSense financials page.
- Revenue
- $0
- Net Income
- -$952K
- EPS
- $-0.41
- Total Assets
- $2M
- Operating Cash Flow
- -$300K
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q2 FY2026 | $0 | -$952K | -$0.41 | -$300K | |
| Q1 FY2026 | $0 | -$1M | -$0.59 | -$1M | |
| Q4 FY2025 | $3K | -$893K | -$0.40 | -30233.33% | -$553K |
| Q3 FY2025 | $0 | -$1M | -$0.55 | -$941K | |
| Q2 FY2025 | $0 | -$1M | -$0.63 | -$701K |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $5K | -$4M | -$2.20 | -84500% | -$3M |
| FY2024 | $10K | -$5M | -$2.92 | -48120% | -$5M |
| FY2023 | $5K | -$35M | -$21.97 | -685340% | -$30M |
Frequently asked questions
What was Alaunos Therapeutics, Inc.'s revenue last quarter?
Alaunos Therapeutics, Inc. reported revenue of $0.00 for Q2 FY2026.
Is Alaunos Therapeutics, Inc. profitable?
Not in its most recent reported period. Alaunos Therapeutics, Inc. reported a net loss of $952.0 thousand for Q2 FY2026.
How much free cash flow did Alaunos Therapeutics, Inc. generate?
Alaunos Therapeutics, Inc. generated free cash flow of -$300.0 thousand in Q2 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Alaunos Therapeutics, Inc. Common Stock on SentiSense, with up to forty quarters and twenty fiscal years of history.